6[10]Avigan D,Vasir B,Gong J,et al.Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses.Clin Cancer Res[J].2004,10(14):4699-4708.
9[14]Brink MF,Bishop MD,Pieper FR.Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk[J].Theriogenology.2000,53(1):139-142
10[15]Zakhartchenko V,Sehernthaner W,Prelle K,et al.Nuclear transfer in the bovine embryo:developmental potential of cultured adult cells[J].Theriogenology.1999,51:218.
5Padlan E A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties [ J ]. Molecuar Immunology,1991,28:489.
6Cristina C, Ver nica P C V, Daniel J, et al. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen[J]. Protein Engineering,2000,13(5) : 353.
7Younes A, Hariharan K, Allen R S, et al. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma[J].Clinical lymphoma ,2003,3(4) :257.
8Choy E H, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens[J]. Arthritis Rheum, 1996,39: 52.
9Davis C G,Gallo M L,Corvalan J R F. Transgenic mice as a source of fully human antibodies for the treatment of cancer[J]. Cancer and Metastasis Reviews, 1999,12(18): 421.
10Chadd H E,Chamow S M. Therapeutic antibody expreesion technology [J]. Current Opinion in Biotechnology, 2001,78:56.
